PURPOSE: Cytokines have been detected in the urine during the first hours after intravesical Bacillus Calmette Guerin (BCG) treatment against superficial bladder cancer. To investigate the long-lasting mucosal inflammatory response, we analyzed intracellular cytokines by immunohistochemistry in biopsies taken 2 weeks after BCG treatment. MATERIALS AND METHODS: Tumor biopsies were obtained from 8 patients with noninvasive, papillary transitional cell carcinoma (TCC), and intracellular cytokines were visualized by immunohistochemistry using cytokine-specific monoclonal antibodies. RESULTS: Interleukin (IL)-1 beta+ or tumor necrosis factor (TNF)-alpha+ cells were abundant in tumor and stroma. Interleukin-1 alpha, IL-2, IL-4, IL-8 and TNF-beta were variably expressed, while IL-10+ and interferon (IFN)-gamma+ cells were not detected. Among the few patients studied (5 responders and 3 nonresponders to BCG treatment) no single cytokine or cytokine profile was associated with clinical response to BCG therapy. CONCLUSION: We conclude that the in situ cytokine response after BCG treatment is highly complex, since cytokine profiles differed among the 8 patients investigated and between tumor and surrounding tumor-free mucosa. Further studies, investigating larger numbers of patients, is required to clarify whether cytokine profiles correlate with the clinical response to BCG.
PURPOSE: Cytokines have been detected in the urine during the first hours after intravesical Bacillus Calmette Guerin (BCG) treatment against superficial bladder cancer. To investigate the long-lasting mucosal inflammatory response, we analyzed intracellular cytokines by immunohistochemistry in biopsies taken 2 weeks after BCG treatment. MATERIALS AND METHODS:Tumor biopsies were obtained from 8 patients with noninvasive, papillary transitional cell carcinoma (TCC), and intracellular cytokines were visualized by immunohistochemistry using cytokine-specific monoclonal antibodies. RESULTS: Interleukin (IL)-1 beta+ or tumor necrosis factor (TNF)-alpha+ cells were abundant in tumor and stroma. Interleukin-1 alpha, IL-2, IL-4, IL-8 and TNF-beta were variably expressed, while IL-10+ and interferon (IFN)-gamma+ cells were not detected. Among the few patients studied (5 responders and 3 nonresponders to BCG treatment) no single cytokine or cytokine profile was associated with clinical response to BCG therapy. CONCLUSION: We conclude that the in situ cytokine response after BCG treatment is highly complex, since cytokine profiles differed among the 8 patients investigated and between tumor and surrounding tumor-free mucosa. Further studies, investigating larger numbers of patients, is required to clarify whether cytokine profiles correlate with the clinical response to BCG.
Authors: F Pagès; S Lebel-Binay; A Vieillefond; L Deneux; M Cambillau; O Soubrane; B Debré; D Tardy; J-L Romet Lemonne; J-P Abastado; W-H Fridman; N Thiounn Journal: Clin Exp Immunol Date: 2002-02 Impact factor: 4.330
Authors: Patrick Vianna Garcia; Fábio Rodrigues Ferreira Seiva; Amanda Pocol Carniato; Wilson de Mello Júnior; Nelson Duran; Alda Maria Macedo; Alexandre Gabarra de Oliveira; Rok Romih; Iseu da Silva Nunes; Odilon da Silva Nunes; Wagner José Fávaro Journal: BMC Cancer Date: 2016-07-07 Impact factor: 4.430
Authors: H P Marsh; N A Haldar; M Bunce; S E Marshall; K le Monier; S L Winsey; K Christodoulos; D Cranston; K I Welsh; A L Harris Journal: Br J Cancer Date: 2003-09-15 Impact factor: 7.640